N-[2-[[2-[(2R,3R,4R,5R)-4-[2-cyanoethoxy-[di(propan-2-yl)amino]phosphoryl]oxy-5-[[(4-methoxyphenyl)-diphenylmethoxy]methyl]-2-[6-oxo-2-[(2-phenoxyacetyl)amino]-1H-purin-9-yl]oxolan-3-yl]oxyacetyl]amino]ethyl]-2,2,2-trifluoroacetamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 三苯基化合物
• 英文名称: N-[2-[[2-[(2R,3R,4R,5R)-4-[2-cyanoethoxy-[di(propan-2-yl)amino]phosphoryl]oxy-5-[[(4-methoxyphenyl)-diphenylmethoxy]methyl]-2-[6-oxo-2-[(2-phenoxyacetyl)amino]-1H-purin-9-yl]oxolan-3-yl]oxyacetyl]amino]ethyl]-2,2,2-trifluoroacetamide
• 化学式: C₅₃H₅₉F₃N₉O₁₂P
• 分子量: 1102.1
• InChiKey: QWZGYMKOSQWGFX-RDZOUKIHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  78
• 可旋转键数：
  26
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  255
• 氢给体数：
  4
• 氢受体数：
  18

文献信息

• Cell-Penetrating Oligonucleotides
  申请人：OLIGOMER SCIENCES AB

  公开号：US20160008389A1

  公开（公告）日：2016-01-14

  The present invention relates to modified oligonucleotides of 5-50 nucleotide residues, wherein at least 25% of the nucleotides are independently modified at the 2′ position to comprise the structure of formula (I), wherein base is a purine or pyrimidine moiety; and R 1 , R 2 , R 3 , R 4 , p and q are as defined in the description. The modified oligonucleotides comprising said structures are useful as medicaments for enhancement of drug uptake in oligonucleotide based therapy in humans and animals.

  本发明涉及5-50个核苷酸残基的修饰寡核苷酸，其中至少25％的核苷酸在2'位独立修饰，包括式（I）的结构，其中碱基是嘌呤或嘧啶基团；且R1，R2，R3，R4，p和q如描述中所定义。包含所述结构的修饰寡核苷酸在人类和动物的寡核苷酸基治疗中用作增强药物摄取的药物。
• CELL-PENETRATING OLIGONUCLEOTIDES
  申请人：Oligomer Sciences AB

  公开号：EP2961757A1

  公开（公告）日：2016-01-06
• US9463200B2
  申请人：——

  公开号：US9463200B2

  公开（公告）日：2016-10-11
• [EN] CELL-PENETRATING OLIGONUCLEOTIDES<br/>[FR] OLIGONUCLÉOTIDES PÉNÉTRANT LES CELLULES
  申请人：OLIGOMER SCIENCES AB

  公开号：WO2014131892A1

  公开（公告）日：2014-09-04

  The present invention relates to modified oligonucleotides of 5-50 nucleotide residues, wherein at least 25% of the nucleotides are independently modified at the 2' position to comprise the structure of formula (I), wherein base is a purine or pyrimidine moiety; and R1, R2, R3, R4, p and q are as defined in the description. The modified oligonucleotides comprising said structures are useful as medicaments for enhancement of drug uptake in oligonucleotide based therapy in humans and animals.